NASDAQ | VICL: 1.24  +0.00
Clinical Trials

Clinical Trials Overview

Vical has filed over fifteen investigational new drug applications to conduct clinical trials and holds master files for manufacturing recombinant DNA products.

Vical has completed more than thirty clinical trials in over 15 countries.

Check back frequently for updates on future enrollments or connect with us through RSS Feeds or connect with us on Vical on LinkedIn or Vical on Twitter.

Ongoing Clinical Trials

Phase 2 Clinical Trial: HSV-2 Therapeutic Vaccine to Treat Genital Herpes in Adults
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults with symptomatic genital HSV-2 infection. For more information, please go to the NCT02837575 trial listing at

Phase 2 Clinical Trial: VL-2397 Antifungal for the Treatment of Invasive Aspergillosis
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients. For more information, please go to the NCT03327727 trial listing at


P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.